In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin

European Journal of Cancer Part A

Volumn 32, Issue 11, 1996, Pages 2011-2018

  Belvedere, G ^a   Imperatori, L ^a   Damia, G ^a   Tagliabue, G ^a   Meijer, C ^b   De Vries, E G E ^b   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Cisplatin; DNA damage; In vivo; Resistance

Indexed keywords

CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IPROPLATIN; MELPHALAN; TALLIMUSTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DNA CROSS LINKING; DNA DAMAGE; DRUG RESISTANCE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETICULOSARCOMA;

EID: 0030272692     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00235-3     Document Type: Article

References (33)

1. 1. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985, 55, 2303-2316.
2. 2. Ozols RF, Young RC. Chemotherapy of ovarian cancer. Semin Oncol 1984, 11, 251-263.
3. 3. Hansworth JD, Grosh WN, Burnett LS. Advanced ovarian cancer: long term results of treatment with intensive cisplatin based chemotherapy of brief duration. Ann Intern Med 1988, 108, 165-170.
4. 4. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990, 2, 35-43.
5. 5. Wolf CR, Hayward IP, Lawrie SS, et al. Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer 1987, 39, 696-701.
6. 6. Simmonds AP, McDonald EC. Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay. Br J Cancer 1984, 50, 317-326.
7. 7. Ferrari A, Damia G, Erba E, Rossi C, Mandelli R, D'Incalci M. Characterization of a novel mouse reticular cell sarcoma M5076 subline resistant to cisplatin. Int J Cancer 1989, 43, 1091-1097.
8. 8. Balconi G, Damia G, Morali F, et al. cis-Diamminedichloroplatinum sensitivity of murine reticulum sarcoma cells in primary culture and after in vitro passages. In Vitro Cell Dev Biol 1993, 29A, 617-619.
9. 9. Talmadge JE, Key ME, Hart IR. Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. Cancer Res 1981, 41, 1271-1280.
10. 10. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: application to mammalian blood and other tissues. Analyt Biochem 1969, 27, 502-522.
11. 11. Habig WH, Pabst MJ, Jakoby WG. Glutathione-S-transferases. The first step in mercapturic acid formation. J Biol Chem 1974, 249, 7130-7139.
12. 12. Kohn KW, Ewig RAG, Erickson LC, Zwelling LA. Measurements of strand breaks and cross-links by alkaline elution. In Friedberg EC, Hanawalt PC, eds. DNA Repair: A Laboratory Manual of Research Techniques. New York, Marcell Dekker, 1981, 379-401.
13. 13. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berends F. cis-Diamminedichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after single dose of cis-diamminedichloro-platinum(II). Cancer Res 1987, 47, 3000-3004.
14. 14. Sark MWJ, Timmer-Bosscha H, Meijer C, et al. Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 1995, 71, 684-690.
15. 15. Schabel FM Jr, Trader MW, Laster WR, Wheeler GP, Witt MH. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 1978, 23, 200-215.
16. 16. Andrews PA, Jones JA, Varki NM, Howell SB. Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 1990, 2, 93-100.
17. 17. Frei III E, Cucchi CA, Rosowsky A, et al. Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 1985, 82, 2158-2162.
18. 18. Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei III E. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res 1986, 46, 4379-4383.
19. 19. Kasahara K, Fujiwara Y, Sugimoto Y, et al. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines. J Natl Cancer Inst 1992, 84, 113-118.
20. 20. Eastman A, Schulte N, Sheibani N, Sorenson CM. Mechanisms of resistance to platinum drugs. In Nicolini M, ed. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Boston, Martinus Nejoff, 1988, 178-196.
21. 21. Meijer C, Mulder NH, de Vries EGE. The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin. Cancer Treat Rev 1990, 17, 389-407.
22. 22. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987, 34, 155-166.
23. 23. Meyn RE, Jenkins SF, Thompson LH. Defective removal of DNA cross-links in a repair deficient mutant of chinese hamster cells. Cancer Res 1982, 42, 3106-3110.
24. 24. Rawlings CJ, Roberts JJ. Walker rat carcinoma cells are exceptionally sensitive to cis-diaminedichloroplatinum(II) (cisplatin) and other difunctional agents but not defective in the removal of platinum-DNA adducts. Mutat Res 1986, 166, 157-168.
25. 25. Bedford P, Fichtinger-Schepman AMJ, Shellard SA, Walker MC, Masters JRW, Hill BT. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 1988, 48, 3019-3024.
26. 26. Shellard SA, Hosking LK, Hill BT. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro. Cancer Res 1991, 51, 4557-4564.
27. 27. Shellard SA, Fichtinger-Schepman AMJ, Lazo JS, Hill BT. Evidence of differential cisplatin-DNA adduct formation, removal and tolerance of DNA damage in three human lung carcinoma cell lines. Anticancer Drugs 1993, 4, 491-500.
28. 28. Hill BT, Scanlon KJ, Hansson J, et al. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer 1994, 30A, 832-837.
29. 29. Kelland LR, Mistry P, Abel G, et al. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 1992, 52, 1710-1716.
30. 30. Larminat F, Zhen W, Bohr VA. Gene-specific DNA repair of interstrand cross-links induced by chemotherapeutic agents can be preferential. J Biol Chem 1993, 268, 2649-2654.
31. 31. Langton-Webster BC, Xuan JA, Brink JR, Salomon DS. Development of resistance to cisplatin is associated with decreased expression of the gp185c-erb-2 protein and alterations in growth properties and responses to therapy in an ovarian tumor cell line. Cell Growth Differ 1994, 5, 1367-1372.
32. 32. Riganti F, Sironi M, Kankova M, et al. The unique interaction with immunity of FCE 24517, antitumor drug with novel mode of action. Int J Immunopharmacol 1992, 14, 239-251.
33. 33. Jackman AL, Taylor GA, Calvert AH, Harrap KR. Modulation of anti-metabolite effects of thymidine on the efficacy of the quinazoline-based thymidilate synthetase inhibitor, CB3717. Biochem Pharmacol 1984, 33, 3269-3275.